Psyence Biomedical Ltd.
Narrative signal
Psyence Biomedical Ltd.’s revenue growth stands at 0% for Mar 2025. Year-over-year, the metric shifted by +0 pts, translating into a – rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
Valuation Signals
Track how the market prices earnings, book value, and operating cash flow for rapid context on relative multiples.
Profitability Pulse
Follow margin structure and return ratios that benchmark execution quality and capital efficiency.
Growth Momentum
Gauge the trajectory of revenue, earnings, and free cash flow expansion to understand durability.
Cash & Balance Sheet
Monitor liquidity, leverage, and free cash flow capacity that underpin resilience across cycles.
AlphaPilot quick take
• Psyence Biomedical Ltd. trades at $1.79 with a market footprint around $1.3M.
• Operating within Healthcare — Biotechnology offers instant peer context.
• Dashboard highlight: revenue growth at 0%, refreshed from the live fundamentals feed.
• Pivot into AlphaPilot deep dives to benchmark valuation, execution, and resilience.
Company profile
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.
Psyence Biomedical Ltd. (PBM) stock FAQs
Quick answers sourced from live Financial Modeling Prep fundamentals and AlphaPilot portfolio guidance.
What is Psyence Biomedical Ltd. (PBM) stock price today?
Psyence Biomedical Ltd. (PBM) trades near $1.79 as of Nov 20, 2025, 7:40 PM. Quotes refresh throughout the trading day in USD via Financial Modeling Prep, which powers the AlphaPilot dashboard.
What is Psyence Biomedical Ltd.'s market capitalization?
Psyence Biomedical Ltd.'s equity is valued around $1.3M, based on the latest share price multiplied by shares outstanding reported to Financial Modeling Prep.
What is the 52-week range for Psyence Biomedical Ltd.?
Psyence Biomedical Ltd.'s 52-week range runs from $1.76 — $62.96. Comparing the current price to this band helps visualize positioning versus the past year's highs and lows.
How active is trading in Psyence Biomedical Ltd. stock?
Psyence Biomedical Ltd. most recently moved about 19.6M shares. Elevated volume often signals strong investor interest or fresh catalysts.
Does Psyence Biomedical Ltd. pay a dividend?
Psyence Biomedical Ltd. currently yields roughly 0%. Dividend yield divides the last 12 months of payouts by the latest share price, providing a quick income snapshot.
What is Psyence Biomedical Ltd.'s intraday trading range?
Psyence Biomedical Ltd. has traded between $1.76 — $2.29 so far today. Monitoring the intraday span highlights short-term volatility relative to the longer 52-week range.
Where does the Psyence Biomedical Ltd. stock data come from?
AlphaPilot sources quotes, fundamentals, and intraday chart data for Psyence Biomedical Ltd. from the Financial Modeling Prep institutional API. The summary page blends live pricing with fundamentals that refresh after every earnings release or regulatory filing.